Amendment: SEC Form SC 13G/A filed by REGENXBIO Inc.

11/14/24 9:00:57 PM ET

$RGNX

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $RGNX alert in real time by email

SC 13G/A 1 tm2427858d8_sc13ga.htm SC 13G/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 2)

REGENXBIO Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

75901B107

(CUSIP Number)

September 30, 2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 75901B107

1	Name of Reporting Person Redmile Group, LLC
2	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) ¨
3	SEC Use Only
4	Citizenship or Place of Organization Delaware
number of shares beneficially owned by each reporting person with		5	Sole Voting Power 0
		6	Shared Voting Power 4,942,312 ⁽¹⁾
		7	Sole Dispositive Power 0
		8	Shared Dispositive Power 4,942,312 ⁽¹⁾
9	Aggregate Amount Beneficially Owned by Each Reporting Person 4,942,312 ⁽¹⁾
10	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11	Percent of Class Represented by Amount in Row (9) 9.9% ⁽²⁾
12	Type of Reporting Person (See Instructions) IA, OO

⁽¹⁾Redmile Group, LLC’s (“Redmile”) beneficial ownership of the Issuer’s common stock (“Common Stock”) is comprised of 4,892,902 shares of Common Stock owned by certain private investment vehicles and/or sub-advised accounts managed by Redmile, including Redmile Biopharma Investments III, L.P. (“RBI III”). Subject to the Beneficial Ownership Blocker (as defined below), Redmile may also be deemed to beneficially own 1,324,740 shares of Common Stock issuable upon exercise of certain pre-funded warrants to purchase Common Stock (the “Warrants”). Pursuant to the terms of the Warrants, the Issuer may not effect any exercise of the Warrant, and a holder of a Warrant does not have the right to exercise the Warrant held by such holder, to the extent that after giving effect to such issuance after exercise, the holder (together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates), would beneficially own in excess of 9.99% (the “Beneficial Ownership Limitation”) of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issued upon exercise of the Warrant (the “Beneficial Ownership Blocker”). The Beneficial Ownership Limitation may be changed at a holder’s election upon 61 days’ notice to the Issuer. The 4,942,312 shares of Common Stock reported as beneficially owned by Redmile in this Schedule 13G represent 9.99% of the outstanding shares of Common Stock (calculated in accordance with footnote (2) below). The reported securities may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles and/or sub-advised accounts. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile. Redmile and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

⁽²⁾Percentage based on the sum of (a) 49,423,188 shares of Common Stock outstanding as of July 25, 2024, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024 filed with the Securities and Exchange Commission on August 1, 2024 (the “Form 10-Q”), plus (b) 49,410 shares of Common Stock issuable upon exercise of the Warrants, which due to the Beneficial Ownership Limitation is the maximum number of shares that could be issued upon exercise of the Warrants.

CUSIP No. 75901B107

1	Name of Reporting Person Jeremy C. Green
2	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) ¨
3	SEC Use Only
4	Citizenship or Place of Organization United Kingdom
number of shares beneficially owned by each reporting person with		5	Sole Voting Power 0
		6	Shared Voting Power 4,942,312 ⁽³⁾
		7	Sole Dispositive Power 0
		8	Shared Dispositive Power 4,942,312 ⁽³⁾
9	Aggregate Amount Beneficially Owned by Each Reporting Person 4,942,312 ⁽³⁾
10	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11	Percent of Class Represented by Amount in Row (9) 9.9% ⁽⁴⁾
12	Type of Reporting Person (See Instructions) IN, HC

⁽³⁾ Jeremy C. Green’s beneficial ownership of Common Stock is comprised of 4,892,902 shares of Common Stock owned by certain private investment vehicles and/or sub-advised accounts managed by Redmile, including RBI III. Subject to the Beneficial Ownership Blocker, Mr. Green may also be deemed to beneficially own 1,324,740 shares of Common Stock issuable upon exercise of the Warrants. Pursuant to the terms of the Warrants, the Issuer may not effect any exercise of the Warrant, and a holder of a Warrant does not have the right to exercise the Warrant held by such holder, to the extent that the Beneficial Ownership Blocker applies. The 4,942,312 shares of Common Stock reported as beneficially owned by Mr. Green in this Schedule 13G represent 9.99% of the outstanding shares of Common Stock (calculated in accordance with footnote (4) below). The reported securities may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles and/or sub-advised accounts. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile. Redmile and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

⁽⁴⁾ Percentage based on the sum of (a) 49,423,188 shares of Common Stock outstanding as of July 25, 2024, as reported in the Form 10-Q, plus (b) 49,410 shares of Common Stock issuable upon exercise of the Warrants, which due to the Beneficial Ownership Limitation is the maximum number of shares that could be issued upon exercise of the Warrants.

CUSIP No. 75901B107

1	Name of Reporting Person Redmile Biopharma Investments III, L.P.
2	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) ¨
3	SEC Use Only
4	Citizenship or Place of Organization Delaware
number of shares beneficially owned by each reporting person with		5	Sole Voting Power 0
		6	Shared Voting Power 3,007,807 ⁽⁵⁾
		7	Sole Dispositive Power 0
		8	Shared Dispositive Power 3,007,807 ⁽⁵⁾
9	Aggregate Amount Beneficially Owned by Each Reporting Person 3,007,807 ⁽⁵⁾
10	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11	Percent of Class Represented by Amount in Row (9) 6.1% ⁽⁶⁾
12	Type of Reporting Person (See Instructions) PN

⁽⁵⁾RBI III’s beneficial ownership of Common Stock is comprised of 2,958,397 shares of Common Stock. Subject to the Beneficial Ownership Blocker, RBI III may also be deemed to beneficially own 869,603 shares of Common Stock issuable upon exercise of the Warrants directly held by RBI III. Pursuant to the terms of the Warrants, the Issuer may not effect any exercise of any Warrant, and a holder of a Warrant does not have the right to exercise any portion of the Warrant held by such holder, if the Beneficial Ownership Blocker applies. The shares of Common Stock reported as beneficially owned by RBI III in this Schedule 13G represent the shares of Common Stock held directly by RBI III and the 49,410 shares of Common Stock that could be issued to RBI III upon exercise of certain of the Warrants directly held by RBI III under the Beneficial Ownership Blocker.

⁽⁶⁾ Percentage based on the sum of (a) 49,423,188 shares of Common Stock outstanding as of July 25, 2024, as reported in the Form 10-Q, plus (b) 49,410 shares of Common Stock issuable upon exercise of the Warrants directly held by RBI III, which due to the Beneficial Ownership Limitation is the maximum number of shares that could be issued upon exercise of the Warrants.

Item 1.

(a)

Name of Issuer

REGENXBIO Inc.

(b)

Address of Issuer’s Principal Executive Offices

9804 Medical Center Drive

Rockville, MD 20850

Item 2.

(a)

Names of Persons Filing

Redmile Group, LLC
Jeremy C. Green

Redmile Biopharma Investments III, L.P.

(b)

Address of Principal Business office or, if None, Residence

Redmile Group, LLC

One Letterman Drive
Building D, Suite D3-300
The Presidio of San Francisco
San Francisco, California 94129

Jeremy C. Green
c/o Redmile Group, LLC (NY Office)
45 W. 27th Street, Floor 11
New York, NY 10001

Redmile Biopharma Investments III, L.P.

c/o Redmile Group, LLC
One Letterman Drive
Building D, Suite D3-300
The Presidio of San Francisco
San Francisco, California 94129

(c)

Citizenship

Redmile Group, LLC: Delaware
Jeremy C. Green: United Kingdom

Redmile Biopharma Investments III, L.P.: Delaware

(d)

Title of Class of Securities

Common Stock, par value $0.0001 per share

(e)

CUSIP Number

75901B107

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

(k)

Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: __________

Item 4.

Ownership.

(a)

Amount beneficially owned:

Redmile Group, LLC – 4,942,312 ⁽¹⁾
Jeremy C. Green – 4,942,312 ⁽¹⁾

Redmile Biopharma Investments III, L.P. – 3,007,807 ⁽²⁾

(b)

Percent of class:

Redmile Group, LLC – 9.9% ⁽³⁾
Jeremy C. Green – 9.9% ⁽³⁾

Redmile Biopharma Investments III, L.P. – 6.1% ⁽³⁾

(c)

Number of shares as to which Redmile Group, LLC has:

(i)

Sole power to vote or to direct the vote:

(ii)

Shared power to vote or to direct the vote:

4,942,312 ⁽¹⁾

(iii)

Sole power to dispose or to direct the disposition of:

(iv)

Shared power to dispose or to direct the disposition of:

4,942,312 ⁽¹⁾

Number of shares as to which Jeremy C. Green has:

(i)

Sole power to vote or to direct the vote:

(ii)

Shared power to vote or to direct the vote:

4,942,312 ⁽¹⁾

(iii)

Sole power to dispose or to direct the disposition of:

(iv)

Shared power to dispose or to direct the disposition of:

4,942,312 ⁽¹⁾

Number of shares as to which Redmile Biopharma Investments III, L.P. has:

(i)

Sole power to vote or to direct the vote:

(ii)

Shared power to vote or to direct the vote:

3,007,807 ⁽²⁾

(iii)

Sole power to dispose or to direct the disposition of:

(iv)

Shared power to dispose or to direct the disposition of:

3,007,807 ⁽²⁾

⁽¹⁾

Redmile’s and Jeremy C. Green’s beneficial ownership of the Issuer’s Common Stock is comprised of 4,892,902 shares of Common Stock owned by certain private investment vehicles and/or sub-advised accounts managed by Redmile, including RBI III. Subject to the Beneficial Ownership Blocker, Redmile and Mr. Green may also be deemed to beneficially own 1,324,740 shares of Common Stock issuable upon exercise of the Warrants. Pursuant to the terms of the Warrants, the Issuer may not effect any exercise of any Warrant, and a holder of a Warrant does not have the right to exercise any portion of the Warrant held by such holder, if the Beneficial Ownership Blocker applies. The 4,942,312 shares of Common Stock reported as beneficially owned by Redmile and Mr. Green in this Schedule 13G represent 9.99% of the outstanding shares of Common Stock (calculated in accordance with footnote (3) below). The reported securities may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles and/or sub-advised accounts. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile. Redmile and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

⁽²⁾

RBI III’s beneficial ownership of Common Stock is comprised of 2,958,397 shares of Common Stock. Subject to the Beneficial Ownership Blocker, RBI III may also be deemed to beneficially own 869,603 shares of Common Stock issuable upon exercise of the Warrants directly held by RBI III. Pursuant to the terms of the Warrants, the Issuer may not effect any exercise of any Warrant, and a holder of a Warrant does not have the right to exercise any portion of the Warrant held by such holder, if the Beneficial Ownership Blocker applies. The shares of Common Stock reported as beneficially owned by RBI III in this Schedule 13G represent the shares of Common Stock held directly by RBI III and the 49,410 shares of Common Stock that could be issued to RBI III upon exercise of certain of the Warrants directly held by RBI III under the Beneficial Ownership Blocker.

⁽³⁾

Percentage based on the sum of (i) 49,423,188 shares of Common Stock outstanding as of July 25, 2024, as reported by the Issuer in its Form 10-Q, plus (ii) 49,410 shares of Common Stock issuable upon exercise of certain of the Warrants, which due to the Beneficial Ownership Limitation is the maximum number of shares that could be issued upon exercise of the Warrants.

Item 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ¨

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

N/A.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

See the response to Item 4.

Item 8.

Identification and Classification of Members of the Group.

N/A.

Item 9.

Notice of Dissolution of Group.

N/A.

Item 10.

Certifications.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: November 14, 2024

Redmile Group, LLC

By:

/s/ Jeremy C. Green

		Name: Jeremy C. Green
		Title: Managing Member

		/s/ Jeremy C. Green
		Jeremy C. Green

Redmile Biopharma Investments III, L.P.

	By:	Redmile Biopharma Investments III (GP), LLC, its general partner

	By:	/s/ Jeremy C. Green
		Name: Jeremy C. Green
		Title: Managing Member

Get the next $RGNX alert in real time by email

Recent Analyst Ratings for

$RGNX

Date	Price Target	Rating	Analyst
2/11/2025	$38.00 → $14.00	Buy → Neutral	Goldman
2/7/2025	$27.00	Outperform	Raymond James
11/15/2024	$22.00	Overweight	Morgan Stanley
10/10/2024	$18.00	Outperform	Raymond James
6/7/2024	$38.00	Buy	Goldman
3/11/2024	$36.00	Buy	H.C. Wainwright
3/8/2024	$20.00 → $35.00	Sector Perform → Outperform	RBC Capital Mkts
3/6/2024	$37.00	Market Perform → Outperform	Leerink Partners

More analyst ratings

Amendment: SEC Form SC 13G/A filed by REGENXBIO Inc.

11/14/24 9:00:57 PM ET

$RGNX

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $RGNX alert in real time by email

SC 13G/A 1 tm2427858d8_sc13ga.htm SC 13G/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 2)

REGENXBIO Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

75901B107

(CUSIP Number)

September 30, 2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

CUSIP No. 75901B107

1	Name of Reporting Person Redmile Group, LLC
2	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) ¨
3	SEC Use Only
4	Citizenship or Place of Organization Delaware
number of shares beneficially owned by each reporting person with		5	Sole Voting Power 0
		6	Shared Voting Power 4,942,312 ⁽¹⁾
		7	Sole Dispositive Power 0
		8	Shared Dispositive Power 4,942,312 ⁽¹⁾
9	Aggregate Amount Beneficially Owned by Each Reporting Person 4,942,312 ⁽¹⁾
10	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11	Percent of Class Represented by Amount in Row (9) 9.9% ⁽²⁾
12	Type of Reporting Person (See Instructions) IA, OO

CUSIP No. 75901B107

1	Name of Reporting Person Jeremy C. Green
2	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) ¨
3	SEC Use Only
4	Citizenship or Place of Organization United Kingdom
number of shares beneficially owned by each reporting person with		5	Sole Voting Power 0
		6	Shared Voting Power 4,942,312 ⁽³⁾
		7	Sole Dispositive Power 0
		8	Shared Dispositive Power 4,942,312 ⁽³⁾
9	Aggregate Amount Beneficially Owned by Each Reporting Person 4,942,312 ⁽³⁾
10	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11	Percent of Class Represented by Amount in Row (9) 9.9% ⁽⁴⁾
12	Type of Reporting Person (See Instructions) IN, HC

CUSIP No. 75901B107

1	Name of Reporting Person Redmile Biopharma Investments III, L.P.
2	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) ¨
3	SEC Use Only
4	Citizenship or Place of Organization Delaware
number of shares beneficially owned by each reporting person with		5	Sole Voting Power 0
		6	Shared Voting Power 3,007,807 ⁽⁵⁾
		7	Sole Dispositive Power 0
		8	Shared Dispositive Power 3,007,807 ⁽⁵⁾
9	Aggregate Amount Beneficially Owned by Each Reporting Person 3,007,807 ⁽⁵⁾
10	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11	Percent of Class Represented by Amount in Row (9) 6.1% ⁽⁶⁾
12	Type of Reporting Person (See Instructions) PN

Item 1.

(a)

Name of Issuer

REGENXBIO Inc.

(b)

Address of Issuer’s Principal Executive Offices

9804 Medical Center Drive

Rockville, MD 20850

Item 2.

(a)

Names of Persons Filing

Redmile Group, LLC
Jeremy C. Green

Redmile Biopharma Investments III, L.P.

(b)

Address of Principal Business office or, if None, Residence

Redmile Group, LLC

One Letterman Drive
Building D, Suite D3-300
The Presidio of San Francisco
San Francisco, California 94129

Jeremy C. Green
c/o Redmile Group, LLC (NY Office)
45 W. 27th Street, Floor 11
New York, NY 10001

Redmile Biopharma Investments III, L.P.

c/o Redmile Group, LLC
One Letterman Drive
Building D, Suite D3-300
The Presidio of San Francisco
San Francisco, California 94129

(c)

Citizenship

Redmile Group, LLC: Delaware
Jeremy C. Green: United Kingdom

Redmile Biopharma Investments III, L.P.: Delaware

(d)

Title of Class of Securities

Common Stock, par value $0.0001 per share

(e)

CUSIP Number

75901B107

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

(k)

Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: __________

Item 4.

Ownership.

(a)

Amount beneficially owned:

Redmile Group, LLC – 4,942,312 ⁽¹⁾
Jeremy C. Green – 4,942,312 ⁽¹⁾

Redmile Biopharma Investments III, L.P. – 3,007,807 ⁽²⁾

(b)

Percent of class:

Redmile Group, LLC – 9.9% ⁽³⁾
Jeremy C. Green – 9.9% ⁽³⁾

Redmile Biopharma Investments III, L.P. – 6.1% ⁽³⁾

(c)

Number of shares as to which Redmile Group, LLC has:

(i)

Sole power to vote or to direct the vote:

(ii)

Shared power to vote or to direct the vote:

4,942,312 ⁽¹⁾

(iii)

Sole power to dispose or to direct the disposition of:

(iv)

Shared power to dispose or to direct the disposition of:

4,942,312 ⁽¹⁾

Number of shares as to which Jeremy C. Green has:

(i)

Sole power to vote or to direct the vote:

(ii)

Shared power to vote or to direct the vote:

4,942,312 ⁽¹⁾

(iii)

Sole power to dispose or to direct the disposition of:

(iv)

Shared power to dispose or to direct the disposition of:

4,942,312 ⁽¹⁾

Number of shares as to which Redmile Biopharma Investments III, L.P. has:

(i)

Sole power to vote or to direct the vote:

(ii)

Shared power to vote or to direct the vote:

3,007,807 ⁽²⁾

(iii)

Sole power to dispose or to direct the disposition of:

(iv)

Shared power to dispose or to direct the disposition of:

3,007,807 ⁽²⁾

⁽¹⁾

⁽²⁾

⁽³⁾

Item 5.

Ownership of Five Percent or Less of a Class.

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

N/A.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

See the response to Item 4.

Item 8.

Identification and Classification of Members of the Group.

N/A.

Item 9.

Notice of Dissolution of Group.

N/A.

Item 10.

Certifications.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: November 14, 2024

Redmile Group, LLC

By:

/s/ Jeremy C. Green

		Name: Jeremy C. Green
		Title: Managing Member

		/s/ Jeremy C. Green
		Jeremy C. Green

Redmile Biopharma Investments III, L.P.

	By:	Redmile Biopharma Investments III (GP), LLC, its general partner

	By:	/s/ Jeremy C. Green
		Name: Jeremy C. Green
		Title: Managing Member

Get the next $RGNX alert in real time by email

Recent Analyst Ratings for

$RGNX

Date	Price Target	Rating	Analyst
2/11/2025	$38.00 → $14.00	Buy → Neutral	Goldman
2/7/2025	$27.00	Outperform	Raymond James
11/15/2024	$22.00	Overweight	Morgan Stanley
10/10/2024	$18.00	Outperform	Raymond James
6/7/2024	$38.00	Buy	Goldman
3/11/2024	$36.00	Buy	H.C. Wainwright
3/8/2024	$20.00 → $35.00	Sector Perform → Outperform	RBC Capital Mkts
3/6/2024	$37.00	Market Perform → Outperform	Leerink Partners

More analyst ratings

Amendment: SEC Form SC 13G/A filed by REGENXBIO Inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$RGNX

Amendment: SEC Form SC 13G/A filed by REGENXBIO Inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$RGNX

$RGNX
Analyst Ratings

REGENXBIO downgraded by Goldman with a new price target

Raymond James resumed coverage on REGENXBIO with a new price target

Morgan Stanley resumed coverage on REGENXBIO with a new price target

$RGNX
Press Releases

REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II

REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights

REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy

$RGNX
Insider Trading

Chief Strategy & Legal Officer Christmas Patrick J. covered exercise/tax liability with 4,699 shares, decreasing direct ownership by 3% to 151,411 units (SEC Form 4)

Chief Executive Officer Simpson Curran covered exercise/tax liability with 4,701 shares, decreasing direct ownership by 2% to 252,331 units (SEC Form 4)

Director Fox Allan M. was granted 7,768 shares, increasing direct ownership by 69% to 19,054 units (SEC Form 4)

$RGNX
SEC Filings

REGENXBIO Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

Amendment: SEC Form SCHEDULE 13G/A filed by REGENXBIO Inc.

SEC Form 10-Q filed by REGENXBIO Inc.

$RGNX
Leadership Updates

Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

REGENXBIO Appoints Mitchell Chan as Chief Financial Officer

REGENXBIO Announces Leadership Transition

$RGNX
Financials

REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights

REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights

REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights

$RGNX
Large Ownership Changes